Drugs blocking the interaction between the ligand and its Dependence Receptor

NETRIS Pharma is pioneering innovative therapeutic approaches in oncology by focusing on the development of first-in-class treatments that target Netrin-1, a key player in cancer resistance mechanisms. Their lead asset, NP137, is designed to enhance the efficacy of existing therapies, including chemotherapy, targeted therapy, and immunotherapy, by overcoming resistance that often limits treatment success. The company is actively conducting a comprehensive clinical development plan, which includes multiple trials aimed at evaluating NP137's ability to reduce tumor growth and aggressiveness across various cancer types, such as pancreatic and endometrial cancers.

In addition to its oncology focus, NETRIS Pharma is also addressing endometriosis, a condition affecting many women, by developing a monoclonal antibody targeting Netrin-1. This initiative aims to provide a non-hormonal disease-modifying treatment, filling a significant gap in available therapies. Furthermore, the company is exploring anti-netrin-1 radioligand therapy, which combines radioisotopes with targeting agents to deliver localized radiotherapy, potentially improving diagnostic and therapeutic outcomes in cancer treatment. Through collaborations with esteemed research institutions and a strong emphasis on intellectual property, NETRIS Pharma is establishing itself as a leader in the biopharmaceutical landscape focused on innovative cancer therapies.

France

Our collaborators and partners are driven by a desire to contribute to the development of new ways of fighting cancer. The therapies developed by NETRIS Pharma are based on cellular mechanisms identified by a world-renowned research group.
Located in Léon Bérard Cancer Center (Lyon, France), NETRIS Pharma is a unique model of a biotechnology company integrated within a comprehensive cancer center.

NETRIS Pharma

Company Details